Advanced Melanoma

A patient facing brain surgery finds comfort in "Grey's Anatomy" tropes and a surprise hospital dinner provided by her boyfriend's local restaurant.

Patients with advanced melanoma experienced high response rates when treated with commercial Amtagvi in a real-world clinical study.

The FDA cleared a phase 3 trial for iSCIB1+ after data showed 74% progression-free survival at 16 months for patients with advanced melanoma.

The FDA has granted orphan drug designation to IFx-2.0 for patients with stage 2B to stage 4 cutaneous melanoma.

Dr. Ariel Ostad explains how addressing uncertainty and scananxiety through communication and support can improve the cancer care experience for patients.

The FDA cleared a phase 3 trial of iSCIB1+ for advanced melanoma after phase 2 data showed improved progression free survival versus standard care.